SYRE Q2 2023 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$688,000+10.1% YoY

Gross Profit

$688,000100.0% margin

Operating Income

-$159M-23146.2% margin

Net Income

-$217M-31552.5% margin

EPS (Diluted)

$-56.79

QoQ Revenue Growth

+247.5%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$244M

Total Liabilities

$451M

Stockholders' Equity

-$207M

Cash & Equivalents

$235M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$688,000	$625,000	+10.1%
Gross Profit	$688,000	$150,000	+358.7%
Operating Income	-$159M	-$22M	-610.2%
Net Income	-$217M	-$22M	-872.5%